EVO101 vs QLS12010
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IRAK4 · full Atopic Dermatitis pipeline
EVO101
Developed by Evommune
NCT05579899 · Phase 2 · completed
The study was randomized, triple-blinded, vehicle-controlled, and included 119 participants, with the clinical EASI measure as its primary endpoint. The primary endpoint was not met: the mean EASI change at week 8 was larger with vehicle cream (-62.0%) than with EVO101 (-43.5%).
Reported efficacy
Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): EVO101 Cream -43.5% (Standard Deviation 60.85) vs Vehicle Cream -62% (Standard Deviation 38.78) (missed)
Result source: NCT05579899
QLS12010
Developed by Qilu Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT07344051 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | EVO101 | QLS12010 |
|---|---|---|
| EASI-75 | —Not reported | —Not reported |
| IGA 0/1 with 2-point improvement | —Not reported | —Not reported |
| EASI-90 | —Not reported | —Not reported |
| EASI, % change | -43.5% vs -62%+18.5 vs placeboNCT05579899 | —Not reported |
EASI-75
- EVO101
- —Not reported
- QLS12010
- —Not reported
IGA 0/1 with 2-point improvement
- EVO101
- —Not reported
- QLS12010
- —Not reported
EASI-90
- EVO101
- —Not reported
- QLS12010
- —Not reported
EASI, % change
- EVO101
- -43.5% vs -62%+18.5 vs placeboNCT05579899
- QLS12010
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
QLS12010: no structured comparison results are available for Atopic Dermatitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. EVO101: 4 of 4 rows · QLS12010: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | EVO101 |
|---|---|
| Dropout rate | 5% NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2 |
| Discontinued due to AEs | 0% NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2 |
| Serious AEs | 0% NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2 |
| Most frequent reported AEs | application site pruritus 13.3% (placebo 20.7%) application site pain 10% (placebo 12.1%) application site erythema 6.7% (placebo 17.2%) NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
EVO101
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: EVO101's landscape · QLS12010's landscape